EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the first quarter ended March 31, 2025, and highlighted recent corporate developments. "We continue to make outstanding progress with our two Phase 3 pivotal trials for DURAVYU in wet age- related macular degeneration (AMD) and have a ...